A set of doctors' perspectives on what clinicians see as emerging device technologies in cardiology, orthopedics, and neurology. This article is excerpted from Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, titled "Bringing Follow-on Funding to Heatlh Care."
By David Cassak and Stephen Levin
Windhover Information's annual START-UP Forum, held this year in the beginning of April in Boston, was titled "Bringing Follow-on Funding...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.
Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.
Highlights from day one of the BIO convention include advice for firms hoping to go public, a call for companies to push the US Congress on rare disease priority review vouchers, and updates on next-generation gene therapies.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
